

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Strategic Trading Analysis

Based on the detailed analysis of the provided report (generated for a future date: Feb 7, 2026), here is the positional trading assessment for Torrent Pharmaceuticals Ltd (TORNTPHARM.NS).

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** Daily and Weekly candlestick charts, 3-year history.
 - **Trend Indicators:** EMA 20, 50, 200; Supertrend; MACD.
 - **Momentum/Volatility:** RSI, Bollinger Bands, Volatility Squeeze indicators.
 - **Relative Strength:** Comparison against ^CNXPHARMA sector and RS Score (54.3/100).
 - **Fundamentals:** Revenue/Net Income growth (4-year and 6-quarter view).
 - **Volume:** Distribution/Accumulation day counts and Moving Averages.
- **Data Missing:**
 - **Intraday Granularity:** While a 15-min summary is provided, visual intraday charts for precise entry timing are absent.
 - **Option Chain:** No derivatives data (Open Interest) to gauge market maker sentiment at the 4000 strike.
- **Confidence Level: High.**
 - *Explanation:* The report is technically exhaustive. **Note:** The data is future-dated (Feb 2026). I am analyzing this as a simulation based strictly on the prices and indicators shown in the report context.

Step 2: Analyze the Setup

- **Price Structure:** The stock is in a long-term **Strong Uptrend** (Price > 200 EMA), but currently experiencing an intermediate-term correction. The price (3939) is trading between the 20-day EMA (3967, dynamic resistance) and the 50-day EMA (3893, dynamic support).
- **Momentum Status: Bearish/Weakening.**
 - **MACD (Page 12):** **Bearish** crossover active, with the histogram showing negative momentum.
 - **RSI (Page 16):** Neutral at 48.79. It has cooled off from overbought levels but hasn't hit oversold (30) yet.
 - **Relative Strength (Page 4-5):** The stock is classified as a "Weakening Leader." It is currently underperforming the Pharma sector index (pink zone in RS chart).
- **Volume Analysis (Page 18):** "Distribution Days" were noted recently (Jan 13, Jan 28, Feb 04). This indicates institutional selling into strength, suggesting overhead supply.
- **Support & Resistance:**
 - **Critical Support:** 3893 (EMA 50) and 3839 (Supertrend).
 - **Resistance:** 3967 (EMA 20) and 4066 (Upper Bollinger Band).
- **The Squeeze:** Page 8 notes the Bollinger Band width is narrowing (0.04). A volatility expansion is imminent, but the direction is currently biased slightly downward due to the bearish MACD.

Step 3: Formulate the Recommendation

Verdict: NO (Do not enter at current market price).

Reasoning: The stock is in "No Man's Land." It is below its short-term momentum guide (EMA 20) and has valid distribution (selling) signals. Entering now risks catching a falling knife before it tests the major support at the EMA 50. The "Weakening Leader" status suggests it lacks the immediate relative strength to drive a

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

breakout without a consolidation phase first.

Conditional Plan (Buy the Dip Strategy): The high-probability trade is to buy the test of the 50-day EMA, provided support holds, rather than chasing the breakout.

- **Condition to Buy:** The price must touch the **3890-3900 zone** (confluence of EMA 50 and Lower Bollinger Band) and print a bullish reversal candle (e.g., Hammer or Green Candle closing above the previous day's high). Alternatively, if it refuses to drop, wait for a **Daily Close above 3970** to reclaim the EMA 20.
- **Entry Price: 3910 - 3920** (on the bounce from support) OR **3975** (on momentum reclaim).
- **Stop Loss: 3825** (Closing Basis).
 - *Rationale:* This is just below the Supertrend support (3839) and the recent swing lows. If 3830 breaks, the intermediate trend is violated.
- **Take Profit:**
 - **Target 1: 4080** (Analyst Target & recent consolidation highs).
 - **Target 2: 4200** (Blue sky breakout / upper band expansion).

Candlestick Classification Analysis

Based on the **Candlestick Classification Summary (Page 20)** and the **Candlestick Chart (Page 21)** for **TORNTPHARM.NS**, here is my analysis as a Candlestick Trader using the 5-step classification logic provided.

1. Current Market State: "Buyer Control" (+1)

According to the summary on Page 20, the latest trading session has been classified as **Buyer Control**.

Deconstructing the Signal (Based on the Algorithm): * **Body Strength:** The candle likely had a **moderate bullish body** (estimated between 0.8 to 1.5 ATR). It wasn't an explosive move (which would trigger "Strong Control"), but it was significant enough to register a directional shift. * **Close Position:** The price closed in the upper portion of the daily range. This is crucial-it indicates that buyers held their ground into the close, showing conviction over intraday sellers. * **Volume Validation:** Looking at the volume bars on Page 21 (far right), the volume accompanying this move is moderate. It is likely near the average (0.8x - 1.2x), which prevents the signal from being amplified to a "Strong Control" (+2) but is sufficient to maintain a standard "Buyer Control" (+1) rating.

2. Trend Context: The 10-Day Struggle

The **Recent Trend Score (10-day avg)** is **0.30**.

- **Interpretation:** A score of 0.30 is **weakly bullish**. On a scale where +2 is maximum bullishness, 0.30 suggests that while buyers are technically winning, the battle is fierce.
- **Visual Analysis (Page 21):** Looking at the far right of the chart, the stock recently pulled back from highs near INR 4100 down to the INR 3900 level. The current "Buyer Control" signal appears to be a **reversal candle** attempting to establish support at this level.
- **Distribution Data:** The report shows **123 instances of "No Control"** vs **61 "Buyer Control"**. This tells me TORNTPHARM is a stock that spends a lot of time consolidating (indecision) before making moves. We are currently seeing a decisive move (+1) emerging from that noise.

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

3. Price Action & Volume Dynamics

- **Support Defense:** The chart shows a previous consolidation zone around the INR 3850-INR 3900 level. The recent drop stopped exactly in this zone, and the appearance of a **Buyer Control** candle here confirms that bulls are stepping in to defend this support.
- **Wick Analysis:** The recent candles show some lower wicks, indicating that every time sellers try to push below INR 3880, they are rejected (Step 3 of your algorithm).

4. Prediction: Which side should the future price be?

Prediction: UPSIDE (Bullish Rebound)

Rationale: The market is setting up for a **support bounce**. The classification system has flagged a shift from the recent corrective selling (red candles) to **Buyer Control (+1)**.

- **Immediate Target:** The price is likely to head toward **INR 4000 - INR 4050** to retest the recent breakdown level.
- **The Setup:** This is a classic "Buy the Dip" setup. The trend score (0.30) is positive, preventing a bearish bias, and the latest candle shows buyers have regained control of the daily session.

Caveat (Risk Management): Because the Trend Score is low (0.30) and not high (>1.0), this is not a "momentum breakout" yet. It is a stabilization. * **Watch Level:** If the price drops below the low of this "Buyer Control" candle (approx INR 3880), the signal fails, and we re-enter "Seller Control." * **Confirmation Needed:** Ideally, we want to see a **Volume Multiplier** kick in tomorrow (High Volume > 1.3x avg) to upgrade the signal to "Buyer Strong Control" (+2) for a sustained rally.

Trader's Verdict: The "Buyer Control" classification at this specific chart location acts as a **reversal signal**. Probability favors a move higher back toward INR 4000.

News & Analyst Targets

Here is the latest research and information on **Torrent Pharmaceuticals (TORNTPHARM)** for the week of **February 1-7, 2026**.

1) Latest News for TORNTPHARM This Week (Feb 1-7, 2026)

- **Completion of JB Chemicals Acquisition (Feb 3, 2026):** Torrent Pharmaceuticals announced the successful completion of its strategic acquisition of shares in J.B. Chemicals & Pharmaceuticals. As of February 3, the company acquired the final tranche of shares, bringing its total holding to **48.80%** of JB Chemicals' equity.
- **Board Meeting & Dividend Announcement (Feb 2, 2026):** The company has scheduled a Board of Directors meeting for **February 13, 2026**, to approve the unaudited financial results for Q3 FY26 (quarter ending Dec 31, 2025). They will also consider the declaration of an interim dividend for FY 2025-26.
- **Record Date Set (Feb 3, 2026):** The company has fixed **Thursday, February 19, 2026**, as the "Record Date" for determining shareholders eligible for the interim dividend, subject to board approval.
- **Management Change (Effective Feb 1, 2026):** Geena Malhotra has officially taken over as the new Chief Technology Officer (CTO) effective February 1, 2026.

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

2) Brokerage Upgrades & Downgrades

- **JPMorgan (Jan 27, 2026 - Recent Context):** Maintained a "**Neutral**" rating but **raised** its price target to **INR 3,700** (from INR 3,400). The firm cited revised valuation timelines and steady margins despite some revenue misses in international markets.
- **MarketsMOJO (Feb 6, 2026):** Maintained a "**Buy**" rating, citing positive technical momentum and steady performance in the current calendar year.
- **Consensus View:** The analyst community remains largely positive to neutral. While some individual targets have been adjusted to reflect recent earnings and the JB Chemicals deal execution, the general consensus leans towards "Buy/Accumulate."

3) Other News Impacting TORNTPHARM

- **USFDA Clearance (Direct Impact):** In late January, the USFDA concluded an inspection of Torrent's **Dahej manufacturing facility** with **zero observations**. This is a significant regulatory win that de-risks their US export business and supports positive sentiment this week.
- **Fundraising for Acquisition (Direct Impact):** The company successfully raised approximately **INR 12,500 crore** through non-convertible debentures (NCDs) and commercial papers to fund the JB Chemicals acquisition. This massive debt issuance was rated **AA+ (Stable)** by ICRA, reflecting confidence in Torrent's ability to service this debt.
- **Sector Trends (Indirect Impact):** The broader Indian pharma sector is currently witnessing consolidation, with Torrent's move being one of the largest. Competitors and peers are also focusing on domestic branded generics, validating Torrent's strategy to double down on the Indian market through the JB Chemicals deal.

4) Latest Analyst Targets

Below is a summary of the latest available price targets from major brokerages and analysts.

Brokerage / Analyst	Rating	Target Price (INR)	Date / Status
Trendlyne Consensus	Buy	3,978	Feb 07, 2026 (Avg)
Sharekhan	Buy	4,024	Q3 FY26 Preview
BofA Securities	Buy	4,000	Post-Upgrade
Geojit BNP Paribas	Hold	3,876	Recent Note
Motilal Oswal	Neutral	3,770	FY26 Update
JPMorgan	Neutral	3,700	Jan 27, 2026
ICICI Securities	Hold	3,530	FY26 Update

Disclaimer: Market data and analyst targets are dynamic and subject to change. Please consult with a certified financial advisor before making any investment decisions.


Stock Detailed Analysis Report

TORNTPHARM.NS

Current Price: ₹3939.00

Generated: 2026-02-07 10:31

TORNTPHARM.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	7.15%	10.36%
Net Income	Yes	No	15.39%	34.98%
ROE	Yes	No	4.22%	24.48%
EPS	Yes	No	15.39%	34.98%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.77%	3.55%
Net Income	Yes	7.85%	6.98%
ROE	Yes	6.57%	7.65%
EPS	Yes	7.78%	6.01%

TORNTPHARM.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	54.3/100
:	

== RS RATIOS ==:

1M RS:	1.014 [Leader]
3M RS:	1.119 [Leader]
6M RS:	1.100 [Leader]
1Y RS:	1.143 [Leader]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✗ Medium-term Lagging:	Not lagging
✓ Performance Improving:	3M (+10.9%) > 6M (+9.0%)

Relative Strength Analysis: TORNTPHARM.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



TORNTPHARM.NS - EMA Crossover Summary

EMA 20:	3967.69
EMA 50:	3893.12
EMA 200:	3619.93
Trend Status:	Strong Uptrend
Golden Cross Date:	2022-02-18 00:00:00+05:30
Golden Cross Price:	1277.55


TORNTPHARM.NS EMA Crossover Analysis



TORNTPHARM.NS - Bollinger Bands Summary

Current Price:	3939.00
Upper Band:	4066.54
Middle Band (SMA 20):	3984.78
Lower Band:	3903.03
%B:	0.2200
Band Width:	0.0410
Status:	Lower Half
Signal:	None
Recent Signal 1:	Buy Signal at 2026-01-30 00:00:00+05:30


TORNTPHARM.NS Bollinger Bands (20, 2) Analysis



TORNTPHARM.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	3839.61
Signal Identified On:	2025-11-10

Supertrend Analysis for TORNTPHARM.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




TORNTPHARM.NS - MACD Summary

MACD Line:	25.51
Signal Line:	35.59
Histogram:	-10.09
Trend:	Bearish
Momentum:	Strengthening
Signal:	None

TORNTPHARM.NS Price






TORNTPHARM.NS MACD (12, 26, 9)



TORNTPHARM.NS - Volatility Squeeze Summary

BB Width:	0.0410
ATR:	114.1929
Total Signals:	26
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-30 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze at 2026-01-02 00:00:00+05:30 (Price: 3885.30)
Signal 5:	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 3869.80)


TORNTPHARM.NS - Volatility Squeeze Analysis



TORNTPHARM.NS - RSI-Volume Summary

Current RSI:	48.79
Current Volume:	231319
Volume MA 20:	273344
Bullish Divergences:	1
Bearish Divergences:	1
Bullish Div 1:	Date: 2024-11-19 00:00:00+05:30, Price: 3065.07
Bearish Div 1:	Date: 2025-04-28 00:00:00+05:30, Price: 3328.68

TORNTPHARM.NS RSI-Volume Divergence Analysis



TORNTPHARM.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

33 Signals Detected

:

2025-12-11 [+]:

Buying Exhaustion (Bearish Div)

2026-01-13 [-]:

Distribution Day

2026-01-28 [-]:

Distribution Day



2026-01-30 [-]:

Climax Volume (Churning)

2026-02-04 [-]:

Distribution Day

TORNTPHARM.NS - Volume Analysis



TORNTPHARM.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: **Buyer Control**

Recent Trend Score (10-day avg): 0.30

:

Distribution:

No Control: 123

Buyer Control: 61

Seller Control: 40

Buyer Strong Control: 3

Seller Strong Control: 1

TORNTPHARM.NS - Candlestick Classification



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	3725.73	3939.0	2025-07-14
1 Day	UPTREND (Buy)	3839.61	3939.0	2025-11-10
15 Min	DOWNTREND (Sell)	3965.18	3932.0	2026-02-04

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bullish	Weakening	No Signal

TORNTPHARM.NS - 1 Week (Candlestick + EMAs)




TORNTPHARM.NS - 1 Day (Candlestick + EMAs)



TORNTPHARM.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - TORNTPHARM_main



Trendlyne Snapshot - TORNTPHARM_forecaster

